文献速递关节外科

术中钙卫蛋白侧流免疫分析可辅助疑似假体周围关节感染患者在一期与二期翻修全髋关节置换术间的决策

Intraoperative calprotectin lateral flow immunoassay can assist decision-making between one- and two-stage revision total hip arthroplasty for patients with suspected periprosthetic joint infection.
PubMed 文献 · Bone Joint J · 2024-05-01

研究纳入48例术前未达EBJIS假体周围关节感染(PJI)标准但临床怀疑PJI的翻修全髋关节置换术患者,术中检测滑液钙卫蛋白侧流免疫分析(LFI),≥50 mg/l者行二期翻修,阴性者行一期翻修。钙卫蛋白诊断曲线下面积0.917,敏感度96.2%、特异度90.9%,45/48例(93.8%)诊治与术后EBJIS标准一致。作者认为钙卫蛋白可作为术中决策的有价值工具。

要点

  • 术中滑液钙卫蛋白LFI以50 mg/l为阈值,敏感度96.2%、特异度90.9%。
  • 48例中45例(93.8%)按该算法诊治与术后EBJIS标准一致。
  • 27例钙卫蛋白阳性中25例组织培养和/或超声裂解阳性,21例阴性中1例假阴性。

核心结论

  • 钙卫蛋白可作为术中决策的有价值工具,用于术前无法确立诊断的疑似慢性PJI病例。

研究设计与样本

  • 研究纳入2020年11月至2022年12月在本机构因可能PJI行翻修THA的105例患者中,48例术前有PJI临床怀疑但未达EBJIS PJI标准的48髋(48例)。
  • 术中采用侧流免疫分析(LFI)检测滑液钙卫蛋白,≥50 mg/l视为感染并行二期翻修THA,阴性者行一期翻修。
  • 至少获取5份组织培养,取出的假体送超声裂解处理。

主要发现

  • 钙卫蛋白阳性(≥50 mg/l)27例,其中25例组织培养和/或超声裂解阳性。
  • 钙卫蛋白阴性21例,其中1例假阴性,该例组织培养阳性。
  • 钙卫蛋白曲线下面积0.917,敏感度96.2%,特异度90.9%,阳性预测值92.6%,阴性预测值95.2%,阳性似然比10.6,阴性似然比0.04。
  • 45/48例(93.8%)按包含术中钙卫蛋白检测的算法得到正确诊断和治疗,与术后评估的EBJIS标准一致。

关键数值与推荐

  • 术中滑液钙卫蛋白≥50 mg/l视为感染并行的二期翻修THA。
  • 钙卫蛋白<50 mg/l者行一期翻修THA。

临床怎么用

  • 对于术前临床怀疑PJI但未达EBJIS PJI标准的翻修THA患者,术中可检测滑液钙卫蛋白LFI以辅助一期与二期翻修决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Accurate diagnosis of chronic periprosthetic joint infection (PJI) presents a significant challenge for hip surgeons. Preoperative diagnosis is not always easy to establish, making the intraoperative decision-making process crucial in deciding between one- and two-stage revision total hip arthroplasty (THA). Calprotectin is a promising point-of-care novel biomarker that has displayed high accuracy in detecting PJI. We aimed to evaluate the utility of intraoperative calprotectin lateral flow immunoassay (LFI) in THA patients with suspected chronic PJI. METHODS: The study included 48 THAs in 48 patients with a clinical suspicion of PJI, but who did not meet European Bone and Joint Infection Society (EBJIS) PJI criteria preoperatively, out of 105 patients undergoing revision THA at our institution for possible PJI between November 2020 and December 2022. Intraoperatively, synovial fluid calprotectin was measured with LFI. Cases with calprotectin levels ≥ 50 mg/l were considered infected and treated with two-stage revision THA; in negative cases, one-stage revision was performed. At least five tissue cultures were obtained; the implants removed were sent for sonication. RESULTS: Calprotectin was positive (≥ 50 mg/l) in 27 cases; out of these, 25 had positive tissue cultures and/or sonication. Calprotectin was negative in 21 cases. There was one false negative case, which had positive tissue cultures. Calprotectin showed an area under the curve of 0.917, sensitivity of 96.2%, specificity of 90.9%, positive predictive value of 92.6%, negative predictive value of 95.2%, positive likelihood ratio of 10.6, and negative likelihood ratio of 0.04. Overall, 45/48 patients were correctly diagnosed and treated by our algorithm, which included intraoperative calprotectin measurement. This yielded a 93.8% concordance with postoperatively assessed EBJIS criteria. CONCLUSION: Calprotectin can be a valuable tool in facilitating the intraoperative decision-making process for cases in which chronic PJI is suspected and diagnosis cannot be established preoperatively.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Macheras GA, Argyrou C, Tzefronis D, et al. Intraoperative calprotectin lateral flow immunoassay can assist decision-making between one- and two-stage revision total hip arthroplasty for patients with suspected periprosthetic joint infection. Bone Joint J. 2024. PMID: 38688513. doi:10.1302/0301-620X.106B5.BJJ-2023-0848.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。